Pinning Down Keymed Biosciences Inc.'s (HKG:2162) P/S Is Difficult Right Now

Simply Wall St.02-03

There wouldn't be many who think Keymed Biosciences Inc.'s (HKG:2162) price-to-sales (or "P/S") ratio of 16.2x is worth a mention when the median P/S for the Biotechs industry in Hong Kong is similar ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608810669?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-03 07:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608810669","market":"us","top_or_hot":-1,"title":"Pinning Down Keymed Biosciences Inc.'s (HKG:2162) P/S Is Difficult Right Now","media":"Simply Wall St.","content":"<div>\n<p>There wouldn't be many who think Keymed Biosciences Inc.'s (HKG:2162) price-to-sales (or \"P/S\") ratio of 16.2x is worth a mention when the median P/S for the Biotechs industry in Hong Kong is similar ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/pinning-down-keymed-biosciences-incs-hkg2162-ps-is-difficult\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pinning Down Keymed Biosciences Inc.'s (HKG:2162) P/S Is Difficult Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPinning Down Keymed Biosciences Inc.'s (HKG:2162) P/S Is Difficult Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-03 07:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/pinning-down-keymed-biosciences-incs-hkg2162-ps-is-difficult><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There wouldn't be many who think Keymed Biosciences Inc.'s (HKG:2162) price-to-sales (or \"P/S\") ratio of 16.2x is worth a mention when the median P/S for the Biotechs industry in Hong Kong is similar ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/pinning-down-keymed-biosciences-incs-hkg2162-ps-is-difficult\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/pinning-down-keymed-biosciences-incs-hkg2162-ps-is-difficult","article_id":"2608810669","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/pinning-down-keymed-biosciences-incs-hkg2162-ps-is-difficult","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608810669","pubTimestamp":1770075447,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"There wouldn't be many who think Keymed Biosciences Inc.'s ( HKG:2162 ) price-to-sales (or \"P/S\") ratio of 16.2x is...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B","BK1583":"高瓴概念","BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股"},"translate_title":"目前很难确定Keymed Biosciences Inc.(HKG：2162)的市盈率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1.5},"content_text":"There wouldn't be many who think Keymed Biosciences Inc.'s (HKG:2162) price-to-sales (or \"P/S\") ratio of 16.2x is worth a mention when the median P/S for the Biotechs industry in Hong Kong is similar at about 13.6x.  However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.     This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.  View our latest analysis for Keymed Biosciences SEHK:2162 Price to Sales Ratio vs Industry February 2nd 2026Advertisement How Keymed Biosciences Has Been Performing  Keymed Biosciences certainly has been doing a good job lately as it's been growing revenue more than most other companies.   It might be that many expect the strong revenue performance to wane, which has kept the P/S ratio from rising.  If not, then existing shareholders have reason to be feeling optimistic about the future direction of the share price.      If you'd like to see what analysts are forecasting going forward, you should check out our free report on Keymed Biosciences.  Is There Some Revenue Growth Forecasted For Keymed Biosciences?   Keymed Biosciences' P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.   Retrospectively, the last year delivered an explosive gain to the company's top line.   The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance.  Therefore, it's fair to say the revenue growth recently has been superb for the company.     Shifting to the future, estimates from the eleven analysts covering the company suggest revenue should grow by 42% each year over the next three years.  That's shaping up to be materially lower than the 88% per annum growth forecast for the broader industry.  With this in mind, we find it intriguing that Keymed Biosciences' P/S is closely matching its industry peers.  Apparently many investors in the company are less bearish than analysts indicate and aren't willing to let go of their stock right now.  These shareholders may be setting themselves up for future disappointment if the P/S falls to levels more in line with the growth outlook.    What We Can Learn From Keymed Biosciences' P/S?  It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.  Given that Keymed Biosciences' revenue growth projections are relatively subdued in comparison to the wider industry, it comes as a surprise to see it trading at its current P/S ratio.  When we see companies with a relatively weaker revenue outlook compared to the industry, we suspect the share price is at risk of declining, sending the moderate P/S lower.  This places shareholders' investments at risk and potential investors in danger of paying an unnecessary premium.      There are also other vital risk factors to consider before investing and we've discovered 1 warning sign for Keymed Biosciences that you should be aware of.   Of course, profitable companies with a history of great earnings growth are generally safer bets. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly. Valuation is complex, but we're here to simplify it.Discover if Keymed Biosciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608810669","isCrawlerRequest":true}